Key Highlights

  • Doximity, Inc. (NYSE:DOCS) said, in a release carried on Business Wire, that its clinical AI assistant Ask ranked first on NOHARM, a safety benchmark built by the ARISE group, which the company describes as led by Stanford and Harvard Medical School physicians.
  • For the twelve months, revenue was US$644.9m, up 13%, with GAAP net income of US$196.1m and diluted earnings per share of US$0.98.
  • The network is close to irreplaceable. With more than 85% of US physicians already members, a pharmaceutical marketer wanting specialists at scale has few comparable options, which is why 94% of revenue is subscription-based and margins have been so high.
  • Revenue rose 13% in FY2026, 5% in the March quarter, and is guided to about 4% in FY2027.

A number-one ranking in clinical AI, and a share price down 72%

Doximity, Inc. (NYSE:DOCS) said, in a release carried on Business Wire, that its clinical AI assistant Ask ranked first on NOHARM, a safety benchmark built by the ARISE group, which the company describes as led by Stanford and Harvard Medical School physicians. Across more than 1,100 scenarios, Ask reportedly beat OpenEvidence and frontier general-purpose models.

Two weeks later Doximity trades about 72% below the 52-week high of US$76.51 shown by aggregated market data. That gap dates from 13 May, when full-year results arrived with guidance implying roughly 4% revenue growth and falling adjusted earnings.

What the company does

Doximity runs the dominant professional network for American clinicians. Its FY2026 Form 10-K, filed, reports more than 3 million registered members, including over 85% of US physicians.

The network is free; revenue comes from selling access to it. Pharmaceutical manufacturers buy subscription modules to put clinical messages in front of prescribers; health systems buy hiring and telehealth modules. Subscriptions produced US$608.4m of FY2026's US$644.9m of revenue, almost all of it American.

Around that core sit point-of-care tools meant to keep doctors on the platform daily: Dialer, a telehealth calling product; Scribe, ambient documentation that turns a consultation into a record-ready note; and Ask, formerly branded DoxGPT. More than 140 US health systems have cleared the Clinical AI Suite through governance committees. The 10-K names QGenda, Abridge, OpenAI and Anthropic as competitors.

Latest financial and operating performance

For the twelve months, revenue was US$644.9m, up 13%, with GAAP net income of US$196.1m and diluted earnings per share of US$0.98. Adjusted EBITDA was US$357.8m, a 55.5% margin, though that measure adds back US$121.6m of share-based compensation, about 19% of revenue.

The fourth quarter is where the slowdown shows: revenue of US$145.4m, up only 5%, net income of US$19.1m, diluted EPS of US$0.10 and adjusted EBITDA of US$65.8m at a 45.3% margin.

Cash generation is the strongest part of the story: free cash flow of US$317.5m, up 19%, and US$748.6m of cash and marketable securities at 31 March with no borrowings. Buybacks of US$431.7m, against US$120.3m in FY2025, swung retained earnings to an accumulated deficit of US$51.1m.

Operationally, more than 800,000 active prescribers used the workflow tools in the fourth quarter, nearly half of them the clinical AI. One disclosure stands out: a single customer accounted for 10% or more of revenue in FY2026, a threshold none reached in FY2025 or FY2024.

The catalyst that matters: guidance says spend, the market says prove it

Guidance issued on 13 May puts FY2027 revenue at US$664m-US$676m and adjusted EBITDA at US$323m-US$335m: about US$25m more revenue for US$29m less profit, implying some US$54m of extra cost and a margin falling from 55.5% to about 49%. The first-quarter guide is starker still, with adjusted EBITDA of US$68.5m-US$69.5m against US$79.8m a year earlier.

Two May decisions point the same way. Matt Sonefeldt became chief financial officer and Dr Steven Zatz president, both from 13 May, after CFO Anna Bryson resigned on 13 April following medical leave. Zatz's offer letter sets a US$500,000 bonus "paid quarterly based on achievement of the F27 Pharma sales booking plan". The same day, Doximity said it would embed Scribe and Ask into Aledade Assist, used by independent practices in Aledade's network.

Valuation now reflects the slowdown rather than the ambition. Net of cash, an enterprise value near US$3.1bn is roughly 8.6 times FY2026 adjusted EBITDA and about 12 times free cash flow; aggregated market data shows a trailing price/earnings ratio of 21.7.

The bull case

The network is close to irreplaceable. With more than 85% of US physicians already members, a pharmaceutical marketer wanting specialists at scale has few comparable options, which is why 94% of revenue is subscription-based and margins have been so high.

The balance sheet funds a slow year comfortably: US$748.6m of cash and securities, no debt and US$317.5m of free cash flow, a yield above 8% at today's price. Ask, Scribe and Dialer are not separately monetised, so if daily use lifts subscription pricing the growth arithmetic changes.

The bear case and the risks

Growth keeps halving. Revenue rose 13% in FY2026, 5% in the March quarter, and is guided to about 4% in FY2027. A network with 85% penetration cannot grow by adding doctors; it must extract more from pharmaceutical budgets, and those budgets are not obliging.

Concentration is rising. One customer passing 10% of revenue in FY2026, when none had in the prior two years, cuts against the idea of a diversified advertising base. The 10-K warns revenue "is relatively concentrated within a small number of key customers" and flags seasonality from the budgetary timing of module purchases and marketing programmes.

The margin is being spent, and the adjusted number flatters. Guidance implies adjusted EBITDA falling in absolute terms, and because it excludes US$121.6m of share-based compensation the economic margin is far thinner than 55%; offsetting that dilution consumed US$431.7m of buybacks last year.

Clinical AI may be a cost centre in a commoditising market. The 10-K names OpenAI and Anthropic alongside Abridge as competitors, and the July release positions Ask against OpenEvidence. Medical question-answering is being given away by well-funded rivals, and no revenue is disclosed for the AI tools.

What investors should watch next

. Doximity said on 16 July it will report first-quarter FY2027 results after the close that day. The tests are revenue against US$151m-US$152m, adjusted EBITDA against US$68.5m-US$69.5m, and whether the full-year range survives.

Pharmaceutical bookings. With the president's bonus tied to the FY2027 pharma booking plan, commentary on bookings, renewals and that 10%-plus customer matters most. If margin lands near the guided 49% while growth stays at 4%, the AI investment reads as a cost, not an accelerant.

Capital returns and annual metrics. Watch whether the US$90.5m quarterly buyback pace persists, and note that net revenue retention and the count of customers above US$500,000 of trailing subscription revenue are disclosed annually, not quarterly.

Investor takeaway

Doximity remains a genuinely profitable business with an enviable position: most American doctors are on its network, it turned US$317.5m of last year's US$644.9m of revenue into free cash flow, and it holds US$748.6m of cash and securities with no debt. Its clinical AI is used daily and ranks first on a benchmark cited by the company.

None of that is yet visible in the revenue line. Guidance for the year to March 2027 implies about 4% growth and lower adjusted earnings, and the shares have fallen roughly 72% from their 52-week high in response. At an enterprise value near nine times guided adjusted EBITDA, expectations are already modest. Whether this is an opportunity or a value trap turns on the 6 August update and on pharmaceutical budgets.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.